Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank38
3Y CAGR-50.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-50.4%/yr
vs +88.8%/yr prior
Acceleration
-139.2pp
Decelerating
Percentile
P38
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 6.29% |
| 2024 | 25.09% |
| 2023 | 108.16% |
| 2022 | 51.52% |
| 2021 | 148.47% |
| 2020 | -56.65% |
| 2019 | 130.72% |
| 2018 | 4.05% |
| 2017 | 0.00% |